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Edited by Felix WielandAbstract The Berardinelli-Seip congenital lipodystrophy type 2
(BSCL2) gene encodes an integral membrane protein, called sei-
pin, of unknown function localized to the endoplasmic reticulum
of eukaryotic cells. Seipin is associated with the heterogeneous ge-
netic disease BSCL2, and mutations in an N-glycosylation motif
links the protein to two other disorders, autosomal-dominant distal
hereditary motor neuropathy type V and Silver syndrome. Here,
we report a topological study of seipin using an in vitro topology
mapping assay. Our results suggest that the predominant form
of seipin is 462 residues long and has an Ncyt–Ccyt orientation with
a long luminal loop between the two transmembrane helices.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Seipin is associated with autosomal recessive Berardinelli-
Seip congenital lipodystropy type 2 (BSCL2) characterized
by near absence of adipose tissue and severe insulin resistance
[1]. Recently published results show that seipin is an integral
membrane protein located in the endoplasmic reticulum (ER)
and that two heterozygous mutations in the BSCL2 gene are
associated with autosomal-dominant distal hereditary motor
neuropathy type V and Silver syndrome [2,3]. The two known
mutations aﬀect a highly conserved glycosylation site, and re-
sult in aggregate formation leading to neurodegeneration. The
occurrence of seipin mutations in two disorders aﬀect primar-
ily the peripheral nerves indicating an important role in the
peripheral nervous system [4].
Presumably more than 50% of all eukaryotic proteins are
glycosylated [5] and defective protein glycosylation has been
associated with a variety of human genetic diseases. Recently
a pathogenic role through the gain of a glycosylation site by
missense mutations has been demonstrated and several candi-
date genes were investigated [6].Abbreviations: ER, endoplasmic reticulum; TM, transmembrane;
BSCL, Berardinelli-Seip congenital lipodystropy; BHK cells, baby
hamster kidney cells; SFV, Semliki Forest virus; TMHMM, trans-
membrane hidden Markov model
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doi:10.1016/j.febslet.2006.03.040Northern blot analysis has shown that BSCL2 is transcribed
into at least three diﬀerent mRNAs with sizes ranging from
1.6, 1.8 to 2.2 kb [2,5]. Whereas the 1.8 kb mRNA, corre-
sponding to AF052149, is exclusively expressed in brain and
testis, the 1.6 and 2.2 kb (BC012140, BC009866) mRNAs are
ubiquitously expressed.
The alignment of the human protein with other species sug-
gests that seipin is at least 398 amino acids long [7] but might
include an additional 64 residues at the N-terminus [8]. Due to
an alternative 5 0UTR exon, the 1.6 kb mRNA can only be
translated into a 398 residues long protein. Because of two po-
tential translation initiation sites, both the 1.8 and 2.2 kb
mRNAs potentially code for proteins composed of both 398
and 462 amino acids. The Kozak consensus sequences for
these two translation start sites are both predicted by
www.hri.co.jp/atgpr/ as possible initiation sites.
The N- and C-terminal regions of seipin appear to be vari-
able among species, but a highly conserved central region is
88% identical among human, mouse, rat and chimpanzee. Sei-
pin lacks any recognizable functional domains but has weak
homology to the 550 kDa human and yeast midasin protein
and to the surface protein PspC from Streptococcus pneumo-
nia. Seipin has a conserved CAAX-motif sequence (CSSS) at
the C-terminus, suggesting that it may be prenylated [9].
Despite its central role in severe disorders little information
on the membrane topology of seipin is currently available. The
N-V-S sequon at positions 152–154 (numbering refers to the
462 residues form of the protein) carry an N-linked glycan,
and is therefore located on the luminal side of the ER mem-
brane [2], but the number of transmembrane (TMs) helices
and their orientations relative to the membrane have not been
determined. Diﬀerent topological prediction programs suggest
that seipin has between one and three TM helices [9].
Here, we present an in vitro topological mapping study of hu-
man seipin, using engineered glycosylation sites at both ends of
the protein and in the regions between the putative TMsegments
to determine the membrane orientation. We propose an Ncyt–
Ccyt topology with two TM helices. We further provide both
in vitro and in vivo data suggesting that the longer formof seipin
comprising 462 residues is the predominant form of the protein.2. Materials and methods
2.1. Plasmid constructions
Human seipin constructs were made as previously described [10].
Brieﬂy, for cloning into and in vitro expression from the pGEM1 plas-
mid, the 5 0 end of the BSCL2 gene encoding seipin (462 amino acidsblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) In vivo expression of myc-tagged seipin (lane 1 and 2) in
BHK cells using an SFV vector, and in vitro expression of untagged
seipin in the presence of dog pancreas rough microsomes (lane 4 and 5).
Seipin was expressed from a clone that encodes both the potential 398
and 462 residues long forms (lane 1 and 4), and froma clone that encodes
only the short form (lane 2 and 5). The full-length clone has the natural
Kozak consensus ribosome binding sequence (AGGAAGATGT) at the
5 0 end. A single triangle indicates the 462 amino acid residues long form
of the protein, two triangles indicate the 398 residues long form. Lane 3
shows the in vivo expression of a SFV-LacZ control in BHK cells (LacZ
has a Mw of 116 kDa). The bands around 46 kDa are present in lanes
1–3 and hence represent non-speciﬁc background products. (B) Topol-
ogy prediction for the 462 amino acids long form of human seipin using
the TMHMM prediction method. Seipin is predicted to have two TM
helices (95–117 and 294–316) with the N- and C-terminal tails located in
the cytoplasm. Transmembrane helices (gray rectangles), cytoplasmic
loops (thin black line) and luminal loops (thin gray line) are indicated
above the curves that show the a posteriori probabilities for the diﬀerent
locations.
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introduction of a 5 0 XbaI site, and (ii) by changing the context of the
region immediately upstream of the initiator ATG codon to a Kozak
consensus ribosome binding sequence, GCCACCATGG [10,11]; both
changes were encoded within the 5 0PCR primer. The reverse primer en-
coded the 3 0-end of BCSL2, two stop codons, and a SmaI site for clon-
ing. The BCSL2 gene was ampliﬁed using the Expand Long Template
PCR System from Roche Diagnostics GmbH (Mannheim, FRG) and
cloned into pGEM1 downstream of the SP6 promoter as an XbaI–
SmaI fragment. The ampliﬁed DNA products were puriﬁed using the
QIAquick PCR Puriﬁcation kit from QIAGEN (Hilden, FRG).
Glycosylation acceptor sites were designed as described previously
[12], i.e. by replacing or inserting one or more appropriately positioned
codons for the acceptor tripeptide Asn-Ser-Thr.
Site-speciﬁc mutagenesis was performed using the QuickChange
Site-Directed Mutagenesis kit from Stratagene (La Jolla, USA). All
mutants were conﬁrmed by sequencing of plasmid DNA at BM labbet
AB (Furulund, Sweden). Restriction enzymes were from Promega, Inc.
(Madison, WI, USA).
2.2. In vitro expression
DNA template for in vitro transcription was prepared by transcrip-
tion of the relevant pGEM1-derived plasmid with SP6 RNA polymer-
ase for 1 h at 37 C. mRNA translation in nuclease-treated reticulocyte
lysate supplemented with [35S]Met and dog pancreas rough micro-
somes was performed as described [13] at 30 C for 1 h. Samples were
analyzed by SDS–PAGE, and proteins were visualized in a Fuji FLA-
3000 phosphorimager using the Image Reader V1.8J/Image Gauge V
3.45 software.
2.3. In vivo expression
The seipin cDNA was cloned into the pcDNA 3.1/myc-His vector
Invitrogen (CA, USA) in order to obtain a Myc tag in the C-terminus.
Protein synthesis in baby hamster kidney (BHK) cells using the Semliki
Forest virus (SFV) expression system was carried out as described pre-
viously [14,15]. Brieﬂy, seipin constructs containing natural Kozak
consensus ribosome binding sequence (AGGAAGATGT) under the
SP6 promoter in the SFV vector was linearized for in vitro transcrip-
tion. The resulting RNA was used to transfect BHK cells by electro-
poration. Six hours after electroporation, cells were starved of Met
for 30 min, then labelled with 35S-[Met] for 15 min. Cells were solubi-
lized in lysate buﬀer containing 1% nonidet P-40 and protease inhibi-
tors, immunoprecipitated using an anti-Myc antibody (Invitrogen)
and analysed by SDS–PAGE. Quantiﬁcations were carried out on a
phosphorimager as described above.3. Results
As noted in Section 1, it is unclear whether seipin is trans-
lated from the ﬁrst or second Met in the open reading frame,
corresponding to a total length of either 462 or 398 residues.
To resolve this issue, we expressed seipin from a full-length
cDNA clone that encodes both possible forms. When ex-
pressed in vitro in the presence of dog pancreas rough micro-
somes, the only product seen corresponds to the long form of
the protein, Fig. 1A (lane 4). We also expressed a myc-tagged
version of seipin in BHK cells using an SFV vector. In this
case, one major and one minor product were observed,
Fig. 1A (lane 1), corresponding to the long and short forms.
Since the long form was the predominant one under both
in vitro and in vivo conditions, we decided to focus our study
on this form of seipin and therefore, all residue numbers below
refer to the long form of the protein.
The membrane topology model for human seipin predicted
by the transmembrane hidden Markov model method
(TMHMM) [16] is shown in Fig. 1B. There are two strongly
predicted TM helices (residues 95–117 and 294–316), with a
third, weakly predicted candidate TM helix around residues219–238. To experimentally determine the topology of seipin,
we used a glycosylation mapping approach [17–19] to map
the location of the N- and C-terminal ends of the protein
and of the predicted loop relative to the ER membrane. When
expressed in vitro in the absence of microsomes seipin mi-
grated as a single product. In the presence of microsomes, it
inserted into the microsomal membrane with the predicted
loop in the lumen, as seen by the glycosylation of an endoge-
nous acceptor site for N-linked glycosylation (Asn152-Val-
Ser) present in this domain, Fig. 2A. No N-glycosylation
was observed when the missense mutation N152S of seipin
was expressed in the presence of microsomes. Therefore, the
potential acceptor site Asn306-Phe-Thr that is situated in the
predicted TM segment between residues 294 and 316 is, as ex-
pected, not glycosylated. N-linked glycosylation in the micro-
some system requires a minimum distance of 10–15 residues
between the glycosylation site and the nearest TM segment
[20–22].
Since the wild-type protein has a modiﬁed endogenous N-
linked glycosylation site, we used the N152S mutant for fur-
ther topology mapping experiments. Single glycosylation
acceptor sites (Asn-Ser-Thr) engineered into the N- and C-ter-
minal tails at residues 3 and 423 were not modiﬁed, whereas an
engineered site in the loop at position 254 was eﬃciently gly-
cosylated, Fig. 2B. Fusion of the C-terminal part of seipin (res-
idues 375–462) containing the engineered glycosylation
acceptor site in position 423 to residue 425 in the lumenal C-
Fig. 2. Investigation of human seipin topology by in vitro translation. The position of the Asn-residue in the engineered NST glycosylation acceptor
sites is indicated above each lane. (A) In vitro translation in the absence () or presence (+) of rough microsomes (RM) of the wild type protein and
the N152S mutation. G, glycosylated product; UG, unglycosylated product. (B) In vitro translation in the absence () or presence (+) of rough
microsomes (RM) of constructs N3 and C423 in the N152S and wild type backgrounds, and of construct N254 in the N152S background. G,
glycosylated product; UG, unglycosylated product.
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cient glysosylation of the engineered site (data not shown),
demonstrating that it is not inherently refractive to modiﬁca-
tion. We conclude that the N- and C-termini are facing the
cytosol, whereas the entire region between residues 117 and
294 is exposed to the ER lumen.4. Discussion
This study reports the membrane topology and N-glycosyl-
ation of human seipin, and also provides data suggesting that
the predominant form of seipin is 462 rather than, as originally
proposed, 398 residues long.Fig. 3. Topology model for seipin. Experimentally analysed glycosyl-
ation sites are indicated in black letters. The dashed line indicates the
weakly predicted TM segment (cf., Fig. 1B).We used engineered glycosylation sites to determine the
topology of the seipin protein expressed in a mammalian
in vitrotranscription/translation system supplemented with
dog pancreas microsomes. Glycosylation acceptor sites placed
near the N- and C-termini were not modiﬁed, pointing to a
cytosolic location of both the N- and C-terminus. An engi-
neered glycosylation site in the central predicted luminal loop
(L254) was eﬃciently modiﬁed, and the presence of an endog-
enous glycosylation site (N152) in the same loop also suggests
a luminal location. Using all the experimental data as con-
straints on the TMHMM topology predictor [23], we obtained
the TM model shown in Fig. 3. This model places the most
highly conserved part of seipin, including the endogenous gly-
cosylation site, in the lumen of the ER.
In summary, we present a model for the membrane topology
of the 462-residues long form of seipin, with two TM helices,
the N- and C-terminus in the cytosol, and the conserved cen-
tral domain loop in the lumen of the ER. These results provide
a necessary basis for future functional studies of the seipin
protein.
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